Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.44 |
| ▸ | PDE1A | P54750 | 5/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20723433 | 0.89 | PDE4D (0.44) | PDE4DPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL20739922 | 0.83 | PDE1A (0.46) | PDE4DPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL19206537 | 0.79 | ALDH1A1 (0.49) | PDE4DPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL20739951 | 0.78 | ALDH1A1 (0.51) | PDE4DPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL20739881 | 0.76 | PDE4D (0.43) | PDE4DPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL20723855 | 0.69 | PDE4D (0.45) | PDE4DPDE1APDE1BPDE1CPDE5A | |
| SCHEMBL20723851 | 0.67 | PDE4D (0.43) | PDE4DPDE1APDE1BPDE1CPDE5A | |
| SCHEMBL20739929 | 0.67 | PDE4D (0.45) | PDE4DPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL30394930 | 0.66 | PDE1A (0.57) | PDE4DPDE1APDE1BPDE1C | |
| SCHEMBL20739950 | 0.65 | PDE4D (0.43) | PDE4DPDE1APDE1BPDE1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914273-B | [1,2,4] triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | 伊莱利利公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | ELI LILLY AND COMPANY (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3665174-B1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | LILLY CO ELI (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3665174-B1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | LILLY CO ELI (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2021-05-20 | — | — | US | disclosed |
| CN-110914273-A | [1,2,4] triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | 伊莱利利公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019032383-A1 | [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | PDE3B, PDE3A, PDE5A | PDE4D 9/4885PDE1A 22/4885PDE1B 16/4885 |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | PDE3B, PDE3A, PDE5A | PDE4D 9/4885PDE1A 22/4885PDE1B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.